{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:18:46Z","timestamp":1774376326420,"version":"3.50.1"},"reference-count":24,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,10]]},"DOI":"10.18632\/oncotarget.18312","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T16:24:06Z","timestamp":1496247846000},"page":"83323-83333","source":"Crossref","is-referenced-by-count":13,"title":["Safety of the neprilysin\/renin-angiotensin system inhibitor LCZ696"],"prefix":"10.18632","volume":"8","author":[{"given":"Bo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfei","family":"Helian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Zibo, Zibo, 255036, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengshuang","family":"An","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Qilu Hospital of Shandong University, Ji\u2019nan, 250012, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Samson","year":"1998","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure","volume":"351","author":"Swedberg","year":"1998","journal-title":"Lancet"},{"key":"3","first-page":"607","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"McInnes","year":"1992","journal-title":"J Hypertens"},{"key":"4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Fonarow","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"5","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/01.RES.71.6.1501","article-title":"Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers","volume":"71","author":"Frampton","year":"1992","journal-title":"Circ Res"},{"key":"6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Levy","year":"2004","journal-title":"Am J Hypertens"},{"key":"7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Lefkowitz","year":"2010","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Zhang","year":"2014","journal-title":"Hypertension"},{"key":"9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"Zile","year":"2014","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"McMurray","year":"2012","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13318-016-0328-3","article-title":"Pharmacokinetics, Safety and Tolerability of Sacubitril\/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects","volume":"42","author":"Sunkara","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Zhang","year":"2015","journal-title":"Hypertens Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FJC.0000000000000485","article-title":"Efficacy and safety of crystalline valsartan\/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study","volume":"69","author":"Zhang","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of Sacubitril\/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: the PARAMETER Study","volume":"69","author":"Guo","year":"2017","journal-title":"Hypertension"},{"key":"15","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Masoudi","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Nihoyannopoulos","year":"2016","journal-title":"Eur Heart J"},{"key":"17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Block","year":"2000","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Swedberg","year":"2002","journal-title":"Circulation"},{"key":"19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijcard.2014.11.059","article-title":"Neprilysin inhibitors preserve renal function in heart failure","volume":"179","author":"Krum","year":"2015","journal-title":"Int J Cardiol"},{"key":"20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s11064-009-9919-6","article-title":"Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis","volume":"34","author":"Wolfer","year":"2009","journal-title":"Neurochem Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.2984-08.2009","article-title":"Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice","volume":"29","author":"Mucke","year":"2009","journal-title":"J Neurosci"},{"key":"22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","article-title":"Quantitative methods in the review of epidemiologic literature","volume":"9","author":"Greenland","year":"1987","journal-title":"Epidemiol Rev"},{"key":"23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Laird","year":"1986","journal-title":"Control Clin Trials"},{"key":"24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2016.01.005","article-title":"The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis","volume":"105","author":"Zhang","year":"2016","journal-title":"Pharmacol Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:03:32Z","timestamp":1589202212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":24,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,10,10]]}},"alternative-id":["18312","29137346"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18312","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]}}}